Regencor
Private Company
Funding information not available
Overview
Regencor is a Stanford University spin-out developing a novel biologic therapy for cardiac regeneration post-myocardial infarction. Its lead asset, REG101, is a proprietary recombinant protein shown in animal studies to promote new cardiac muscle growth, reduce scar tissue, and restore function via subcutaneous delivery. The company is currently in IND-enabling studies, targeting human clinical trials in late 2025, and aims to address the significant unmet need in both acute MI and chronic heart failure markets. Leadership includes seasoned biotech executives and the scientific founder who discovered REG101's regenerative properties.
Technology Platform
Proprietary recombinant protein (REG101) platform designed to stimulate cardiomyocyte proliferation and angiogenesis for cardiac tissue regeneration, delivered via non-invasive subcutaneous injection.
Opportunities
Risk Factors
Competitive Landscape
Regencor competes in the cardiac regeneration space, which includes companies developing cell therapies (e.g., mesenchymal stem cells), gene therapies, and other biologics. Its primary competitive differentiation is the combination of a protein-based biologic (potentially simpler than cell/gene therapy) with a non-invasive subcutaneous delivery method, aiming for better safety, manufacturability, and patient access.